Published in Women's Health Weekly, May 1st, 2006
The preclinical studies also identified a novel defect in a protein degradation pathway in the cisplatin-resistant cells. Significantly, this defect enhances the activity of INGN 241, suggesting INGN 241 may have particular utility in treating cancers that do not respond to cisplatin.
The data are published in the Proceedings of the American Association of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly